Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Theracryf Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Huw Jones

İcra Kurulu Başkanı

UK£302.9k

Toplam tazminat

CEO maaş yüzdesi	71.0%
CEO görev süresi	4yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	9yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Oct 11

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Nov 24

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Aug 06

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Apr 09

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Dec 25

CEO Tazminat Analizi

Huw Jones'un ücretlendirmesi Theracryf'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	UK£303k	UK£215k	-UK£3m
Dec 31 2023	n/a	n/a	-UK£3m
Sep 30 2023	n/a	n/a	-UK£3m
Jun 30 2023	n/a	n/a	-UK£4m
Mar 31 2023	UK£305k	UK£200k	-UK£4m
Dec 31 2022	n/a	n/a	-UK£4m
Sep 30 2022	n/a	n/a	-UK£3m
Jun 30 2022	n/a	n/a	-UK£3m
Mar 31 2022	UK£240k	UK£188k	-UK£3m
Dec 31 2021	n/a	n/a	-UK£3m
Sep 30 2021	n/a	n/a	-UK£2m
Jun 30 2021	n/a	n/a	-UK£3m
Mar 31 2021	UK£224k	UK£88k	-UK£3m

Tazminat ve Piyasa: Huw 'ın toplam tazminatı ($USD 402.25K ) UK pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 373.18K ).

Tazminat ve Kazançlar: Huw 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Huw Jones (65 yo)

4yrs

Görev süresi

UK£302,890

Tazminat

Dr. Huw Jones, BSc, Ph D., serves as Non-Executive Director of Ixaka Limited since August 2023. He serves as Chief Executive Officer at Theracryf Plc (formerly known as Evgen Pharma plc) since October 1, 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Huw Jones	CEO & Executive Director	4yrs	UK£302.89k	0.75% £ 23.9k
Toni Haenninen	CFO & Director	1.1yrs	UK£385.25k	0.23% £ 7.5k
Helen Kuhlman	Chief Business Officer	3.5yrs	Veri yok	0.25% £ 7.9k
Glen Clack	Chief Medical Officer	3.4yrs	Veri yok	0.23% £ 7.5k

3.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim: TCF 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Huw Jones	CEO & Executive Director	no data	UK£302.89k	0.75% £ 23.9k
Toni Haenninen	CFO & Director	less than a year	UK£385.25k	0.23% £ 7.5k
Susan Foden	Chair & Senior Independent Director	9.9yrs	UK£36.39k	0.17% £ 5.4k
Alan Barge	Independent Non-Executive Director	9yrs	UK£22.91k	Veri yok

9.0yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TCF 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9 yıldır).

Theracryf Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Insufficient new directors

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Recent updates

New major risk - Share price stability

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024

New minor risk - Financial data availability

Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.

Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.

Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer

Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

New minor risk - Share price stability

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma Studies

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation Approved

New major risk - Market cap size

New minor risk - Share price stability

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Consensus revenue estimates fall by 92%

Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023

Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts Dosed

Consensus forecasts updated

Evgen Pharma plc to Report First Half, 2023 Results on Dec 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Clinical Trial Update

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Receives Regulatory and Ethical Approvals for A Healthy Volunteer, Pharmacokinetic and Pharmacodynamic, Study Toexamine the Performance of the Company's New Enteric Coated Tablet Formulation of Lead Asset SFX-01

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Evgen Pharma plc to Report Fiscal Year 2022 Results on Jun 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Progress Discussions with the UK Medicines and Healthcare Products Regulatory Agency and the US Food and Drug Administration

Insufficient new directors

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Announces Early Data for SFX-01 in Leukaemia Cell Lines

Evgen Pharma plc Announces Glioma Orphan Drug Application Submitted to US FDA

Evgen Pharma plc Announces Progress on Metastatic Breast Cancer Programme

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Evgen Pharma plc Provides Update on Data Safety Review for STAR COVID-19 Trial

Evgen Pharma plc Updates on Patient Recruitment

Evgen Pharma plc, Annual General Meeting, Mar 03, 2021

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Evgen Pharma plc to Report Fiscal Year 2020 Results on Jun 15, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş